[Special Stock] IMBDX, 'Consectidect' Innovative Medical Technology Approved... Detects Cancer Recurrence 3 Weeks After Surgery

IMBDX is showing strong performance. The news that the cancer test product 'CancerDetect' has been approved as an innovative medical technology appears to have had an impact.

As of 3:13 PM on the 25th, IMBDX was trading at 11,160 KRW, up 1,400 KRW (14.34%) from the previous trading day.

On the same day, IMBDX announced that its Minimal Residual Disease (MRD) test product, 'CancerDetect', which can detect cancer recurrence early just three weeks after surgery, has been approved as an innovative medical technology.

Innovative medical technology is a system that supports the rapid introduction of new technological products into medical practice when their safety and potential are recognized according to criteria set by the Minister of Health and Welfare. Therefore, 'CancerDetect' can be applied as non-reimbursable or selectively reimbursable for up to three years. Starting in May, it plans to quickly enter the medical field, focusing on major university hospitals in Korea.

'CancerDetect' is a product that detects minimal residual cancer after cancer surgery and can confirm cancer recurrence up to 20 months earlier than conventional imaging tests. It helps establish treatment strategies based on recurrence risk and contributes to improving patient survival rates.

In particular, it applies technology that can detect unique genetic mutations of cancer cells specific to individual patients, achieving world-class accuracy capable of detecting ultra-minor mutations as low as 0.001%.

The target for this innovative medical technology approval of 'CancerDetect' is stage 2-3 colorectal cancer patients who have undergone radical resection surgery.

According to the revised U.S. NCCN guidelines in February this year, minimal residual disease testing for colorectal cancer patients has already been officially registered as a major prognostic predictor of recurrence in the U.S. Therefore, the approval of 'CancerDetect' as an innovative medical technology is expected to have a positive effect on the introduction of advanced treatment systems in Korea.

IMBDX has confirmed that 'CancerDetect' shows high performance not only in colorectal cancer but also in various cancer types such as breast and stomach cancer, and plans to expand its use to other solid tumors in the future.